Effectiveness And Safety Of Low Dose Vitamin D As An Adjunct Therapy In Patients With Type 2 Diabetes Mellitus: A Double-Blind, Randomised, Controlled Study

Abstract

Background: The metabolic condition Type 2 Diabetes Mellitus causes insulin resistance and beta-cell malfunction. The presence of low-grade inflammation caused by an elevation in the cytokine’s tumour necrosis factor-alpha and interleukin-6 in the blood is the most crucial indicator of T2DM. Given its potent immunosuppressive properties, specific pro-inflammatory cytokine genes, including interleukin-2, interleukin-12, and tumour necrosis factor-alpha, can be inhibited by vitamin D.
Methodology: Participants who satisfied the inclusion criteria and were already getting treatment for type 2 diabetes mellitus were screened from the general medicine outpatient department of a Tertiary Care Hospital in South India for this double-blind, randomised, controlled trial. Participants were split into two groups at random, with group 1 getting capsule vitamin D 6,000IU once a week for 16 weeks while group 2 got a placebo.
Results: Low Dose vitamin D proved to be more effective and safer in controlling HbA1c after 16 weeks compared to placebo.
Conclusion: Vitamin D is proven safe and cost-effective addition to anti-diabetic medicines